Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Aerial licenses narcolepsy compound ADXN05 to Jazz Pharma

Executive Summary

For $125mm in cash up front, Jazz Pharmaceuticals PLC (spec pharma focused on cancer, blood diseases, and neurology) received worldwide development, manufacturing, and marketing rights outside of Asia to start-up Aerial BioPharma LLC’s Phase IIb ADXN05 (formerly SKLN05, ARLN05), a phenylalanine derivative with US orphan drug designation for excessive daytime sleepiness associated with narcolepsy.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Includes Contract
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register